The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

Publication | Open Access

DOI Full Paper Access

202

Citations

References

2021

Year

Anthony G Marson, Girvan Burnside, Richard Appleton, Dave Smith, John Paul Leach, Graeme J. Sills, Catrin Tudur Smith, Catrin Plumpton, Dyfrig Hughes, Paula Williamson,

The Lancet

Abstract

References